The aim of this study is to investigate the efficacy and safety of long-term therapy with Serenoa repens extract with regard to halting benign prostatic hyperplasia progression.
An open non-comparative observational study of the continuous use of S.
To compare the efficacy and safety of oral supplementation with Serenoa repens (SR) and bovine colostrum (BC) plus tamsulosin (TAM) versus TAM alone over 12 months in men suffering from lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is reported in literature ranging from 1 to 14.2%. The aim of the present study was to assess the impact on patient's quality of life and symptoms of Flower pollen extract in association with vitamins (Deprox 500®) in comparison with Serenoa repens 320 mg (Permixon 320 mg® by Pierre Fabre) in patients with CP/CPPS.
BERKELEY, CA (UroToday.com) - Serenoa repens has been the object of intense research into the treatment of symptoms of benign hypertrophy, and recently of infections of the urinary tract.
Benign prostatic hyperplasia (BPH) is a disease affecting most of the elderly male. α1-blockers and 5-alpha reductase inhibitors are currently used to target lower urinary tract symptoms (LUTS).
Login to update email address, newsletter preferences and use bookmarks.